Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics.
Cytosolix has raised $6.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Cytosolix's investors include Connecticut Innovations.
Cytosolix is headquartered in Tolland, United States.
Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics.
Cytosolix is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cytosolix — Funding & Investors." VCBacked, June 28, 2023, https://www.vcbacked.co/company/cytosolix. Accessed July 20, 2026.
VCBacked. (2023). Cytosolix — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/cytosolix
{{cite web |title=Cytosolix — Funding & Investors |url=https://www.vcbacked.co/company/cytosolix |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated